Atossa Therapeutics Inc. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration’s grant of Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for treating McCune-Albright syndrome (MAS) in females. According to PharmaBiz.com, this recognition not only validates the therapeutic potential of the investigational compound but also opens pathways to substantial non-dilutive value through the Priority Review Voucher program.
Understanding McCune-Albright Syndrome
McCune-Albright syndrome is an extremely rare genetic disorder caused by activating mutations in the GNAS gene, resulting in mosaic endocrine dysregulation. The disease presents as a distinctive triad of symptoms: polyostotic fibrous dysplasia, where normal bone is replaced with weak, fibrous tissue causing fractures and deformities; café-au-lait spots, hyperpigmented skin patches with irregular, jagged borders; and hyperfunctioning endocrinopathies—most notably gonadotropin-independent precocious puberty.
In pediatric patients, particularly girls, MAS frequently manifests as early-onset puberty, sometimes as early as age two. This premature sexual development leads to accelerated growth, premature epiphyseal closure, reduced adult height, and additional complications including thyroid dysfunction and growth hormone excess. Given its rarity and diverse symptom spectrum, diagnosis remains challenging, and treatment options are severely limited—highlighting urgent unmet medical need.
A Novel Therapeutic Approach
(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple biological pathways of clinical interest. Atossa’s proprietary oral formulation exhibits a favorable safety profile distinct from tamoxifen, featuring ER-targeted effects and protein kinase C (PKC) inhibition. The drug’s mechanism, particularly its ability to modulate estrogen-driven disease manifestations, positions it as a potentially transformative treatment for hormone dysregulation characteristic of MAS.
According to Janet Rea, Atossa’s senior vice president of research and development, the scientific rationale supporting (Z)-endoxifen in MAS is compelling, and the company is encouraged as it defines the clinical development pathway forward.
Regulatory and Financial Implications
The RPD designation is reserved for serious or life-threatening diseases primarily affecting individuals from birth to 18 years old. Upon FDA approval of a qualifying application, drugs granted RPD designation become eligible for a Priority Review Voucher (PRV), a remarkably valuable asset. Recent disclosed PRV sales have ranged from approximately $100–$205 million, representing significant non-dilutive value for biopharmaceutical companies.
Steven Quay, Atossa’s president and chief executive officer, emphasized that the designation “provides further validation of the potential of (Z)-endoxifen beyond oncology” and creates “potential non-dilutive value through the Rare Paediatric Disease programme.”
Community Engagement and Commitment
Demonstrating commitment to the MAS community, Atossa actively participated in the Fibrous Dysplasia/McCune-Albright Syndrome Alliance Research Priorities Workshop at Children’s Hospital of Philadelphia, collaborating with clinicians, researchers, patients, caregivers, and patient advocacy groups. This engagement underscores the company’s dedication to integrating patient and caregiver perspectives with clinical insights to shape research agendas and accelerate therapeutic development.
Expanding Pipeline Potential
This RPD designation for MAS represents Atossa’s second for (Z)-endoxifen, which also holds RPD status for Duchenne Muscular Dystrophy. The company’s growing global intellectual property portfolio, including recently issued U.S. patents and numerous pending applications, strengthens its position in advancing this versatile therapeutic candidate across multiple rare disease indications, offering hope to patients with previously limited treatment options.
